Navigation Links
Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology
Date:10/24/2007

TARRYTOWN, N.Y., Oct. 24 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Gary Riley has been appointed to the position of Vice President, Nonclinical Development and Applied Biology, effective November 6, 2007. Dr. Riley will be responsible for the oversight and management of nonclinical drug efficacy and safety programs, including regulatory toxicology, and the strategic design of discovery projects. Dr. Riley will report directly to Michael V. Novinski, President and Chief Executive Officer. Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its eligen(R) technology.

"Gary Riley has great hands-on experience in managing all aspects of nonclinical drug development and in bringing issues before the FDA and European Regulatory Agencies," said Michael V. Novinski, President and Chief Executive Officer of Emisphere Technologies, Inc. "Dr. Riley also brings a real expertise in integrating knowledge of the biological response to novel drug delivery technologies and accelerating the product cycle. It is a wealth of experience that we are excited to bring to Emisphere."

Dr. Riley has over 18 years experience as a nonclinical scientist and manager in the biotechnology and pharmaceutical industries. He was the Vice President of Toxicology and Applied Biology at Alkermes, Inc. in Cambridge, Massachusetts, where he directed the design, execution and interpretation of toxicology and nonclinical efficacy programs for a wide range of parenteral drug delivery formulations. Dr. Riley played a key role in obtaining FDA approvals for three novel controlled release formulations at Alkermes in the past seven years, and has directed a large portfolio of nonclinical safety programs for specialized drug formulations targeting CNS diseases, reproduction, hematology, oncology and metabolic diseases. Dr. Riley has also investigated the role of the host response on the functionality of a variety of parenteral and inhalation drug delivery formats.

His prior pharmaceutical experience includes his role as Director of Pathobiology at Lederle Laboratories, where he designed and directed safety assessment programs for product candidates to serve a broad range of medical indications. Dr. Riley also has extensive experience in industrial and government sponsored chemical toxicology research. In academia, he formerly held faculty appointments in veterinary pathology at the University of Illinois and Iowa State University.

"Emisphere is poised to make a significant difference in the lives of millions of patients," said Dr. Riley. "It is an exciting time to join this team and help move the Company to continued, greater success."

Dr. Riley is a veterinarian (BVSc, Sydney University) with graduate qualifications in veterinary pathology (MVSc, Melbourne University and PhD, University of Missouri). He is certified by the American College of Veterinary Pathologists and the American Board of Toxicology. He is the senior author of over 30 nonclinical IND and NDA submissions for the FDA and EU drug registration agencies, and the author of over 30 peer-reviewed publications.

Emisphere's broad-based drug delivery technology platform, known as the eligen(R) technology, is based on the use of proprietary, synthetic chemical compounds, known as Emisphere delivery agents, or "carriers." Emisphere's eligen(R) technology makes it possible to deliver a therapeutic molecule without altering its chemical form or biological integrity.

About Emisphere Technologies, Inc.

Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its eligen(R) technology. These molecules and compounds could be currently available or are in pre-clinical or clinical development. Such molecules or compounds usually cannot be delivered by the oral route of administration or the benefits of these compounds are limited due to poor bioavailability, slow on-set of action or variable absorption. The eligen(R) technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, per rectum, pulmonary, intra-vaginal or transdermal. The Web site is: http://www.emisphere.com.

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, or Emisphere's ability to fund such efforts with or without partners. Emisphere undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 000-17758) filed on March 6, 2007, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, filed on May 7, 2007 (file no. 000-17758).


'/>"/>
SOURCE Emisphere Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen Matloff, ... Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff will ... Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, engineering ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
(Date:3/22/2017)... MONICA, Calif. , March 22, 2017 /PRNewswire/ ... are proud to announce their extended partnership and ... will be headlined by the 21 st ... BIOMEDevice Boston, taking place May 3-4, 2017. ... Advanced Medical Technology Association (ADVAMED) President and CEO, ...
(Date:3/22/2017)... PALM BEACH, Florida , March 22, 2017 ... ... management for various cancer conditions are being pressured as of ... pain therapy for cancer pain management has a dramatic impact ... ramp up research and development activities for identifying new forms ...
Breaking Biology Technology:
(Date:2/27/2017)... 2017   Strategic Cyber Ventures , the industry,s ... a $3.5 million investment in  Polarity , the first ... is DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran ... this series A round of funding. This new funding ...
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a community ... that it has received Laboratory Accreditation from the ... is presented to laboratories that meet stringent requirements ... scientifically rigorous processes. "Genos is committed ... laboratory practices. We,re honored to be receiving CAP ...
Breaking Biology News(10 mins):